Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PELP1 siRNA
- Development stage
- Preclinical
- Lead developer
- UT Health San Antonio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PELP1 siRNA (also known as PELP1-siRNA-DOPC) is a preclinical-stage RNA interference (RNAi) therapeutic consisting of a small interfering RNA sequence targeting the Proline-, Glutamate- and Leucine-rich Protein 1 (PELP1) gene. PELP1 is a nuclear receptor coregulator and proto-oncogene that is overexpressed in several malignancies, including glioblastoma, breast, ovarian, and gastric cancers, where it facilitates tumor progression and metastasis through the modulation of hormonal signaling and the β-catenin pathway. To enable systemic delivery, the siRNA is typically encapsulated in neutral nanoliposomes composed of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). Research conducted primarily at the University of Texas Health Science Center at San Antonio has demonstrated that silencing PELP1 with this therapeutic approach significantly inhibits cell proliferation, migration, and in vivo tumor growth in various xenograft models.
- Other names
- PELP1 siRNAPELP-1 siRNAPELP 1 siRNAPELP1-siRNA-DOPCPELP-1-siRNA-DOPCPELP 1-siRNA-DOPC
02
Targets
Proline-, glutamic acid- and leucine-rich protein 1 (PELP1) mRNA
Beyond the preview
Go deeper on PELP1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PELP1 siRNA.